In PLWH with advanced solid tumors:• Frequency of dose limiting toxicities• Immuno-virological evolution of HIV- infection (HIV-RNA load, CD4 and CD8 T-cell counts, activation and exhaustion markers)• Changes in infiltrating immune cell markers and angiogenesis markers. This evidence concerns the gene CD8A and HIV infectious disease.